Levente Molnár

Levente Molnár

Auto-generated profile, based on publicly available information

Levente Molnár

Heart and Vascular Center, Semmelweis University, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in EuroIntervention
Verified
Journal Article
Closed access
IÉIstván F. Édes
István F. Édes
Zoltán RuzsaZoltán Ruzsa
Zoltán Ruzsa
GSGyörgy Szabó
György Szabó
ÁLÁrpád Lux
Árpád Lux
LGLászló Gellér
László Gellér
BMBéla Merkely
Béla Merkely
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 June 2011 in Heart Rhythm
Verified
Journal Article
Closed access
LGLászló Gellér
László Gellér
SSSzabolcs Szilágyi
Szabolcs Szilágyi
EZEndre Zima
Endre Zima
LMLevente Molnár
Levente Molnár
GSGábor Széplaki
Gábor Széplaki
BMBéla Merkely
Béla Merkely

12 May 2015 in EP Europace
Verified
Journal Article
Open access
PDF file
ABAndrás Mihály Boros
András Mihály Boros
GSGábor Széplaki
Gábor Széplaki
PPPéter Perge
Péter Perge
ZJZsigmond Jenei
Zsigmond Jenei
ZBZsolt Bagyura
Zsolt Bagyura
BMBéla Merkely
Béla Merkely
The low lymphocyte counts and high neutrophil leucocyte fractions have been associated with poor prognosis in chronic heart failure. We hypothesized that the baseline ratio of the neutrophil leucocytes to the lymphocytes (NL ratio) would predict the outcome of chronic heart failure patients undergoing cardiac resynchronization therapy (CRT). The qualitative blood counts and the serum levels of N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) of 122 chronic heart failure patients and 122 healthy controls were analysed prospectively in this observational study. The 2-year mortality was considered as primary endpoint and the 6-month reverse remodelling (≥15% decrease in the end-systolic volume) as secondary endpoint. Multivariable regression analyses were applied and net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated. The NL ratio was elevated in chronic heart failure patients when compared with the healthy controls [2.93 (2.12–4.05) vs. 2.21 (1.64–2.81), P < 0.0001]. The baseline NL ratio exceeding 2.95 predicted the lack of the 6-month reverse remodelling [n = 63, odds ratio = 0.38 (0.17–0.85), P = 0.01; NRI = 0.49 (0.14–0.83), P = 0.005; IDI = 0.04 (0.00–0.07), P = 0.02] and the 2-year mortality [n = 29, hazard ratio = 2.44 (1.04–5.71), P = 0.03; NRI = 0.63 (0.24–1.01), P = 0.001; IDI = 0.04 (0.00–0.08), P = 0.02] independently of the NT-proBNP levels or other factors. The NL ratio is elevated in chronic heart failure and predicts outcome after CRT. According to the reclassification analysis, 4% of the patients would have been better categorized in the prediction models by combining the NT-proBNP with the NL ratio. Thus, a single blood count measurement could facilitate the optimal patient selection for the CRT.

27 June 2015 in EP Europace
Verified
Journal Article
Open access
PDF file
Annamária KosztinAnnamária Kosztin
Annamária Kosztin
VKValentina Kutyifa
Valentina Kutyifa
VNVivien Klaudia Nagy
Vivien Klaudia Nagy
LGLaszlo Geller
Laszlo Geller
EZEndre Zima
Endre Zima
BMBéla Merkely
Béla Merkely
Data on longer right to left ventricular activation delay (RV-LV AD) predicting clinical outcome after cardiac resynchronization therapy (CRT) by left bundle branch block (LBBB) are limited. We aimed to evaluate the impact of RV-LV AD on N-terminal pro–B-type natriuretic peptide (NT-proBNP), ejection fraction (EF), and clinical outcome in patients implanted with CRT, stratified by LBBB at baseline. Heart failure (HF) patients undergoing CRT implantation with EF ≤ 35% and QRS ≥ 120 ms were evaluated based on their RV-LV AD at implantation. Baseline and 6-month clinical parameters, EF, and NT-proBNP values were assessed. The primary endpoint was HF or death, the secondary endpoint was all-cause mortality. A total of 125 patients with CRT were studied, 62% had LBBB. During the median follow-up of 2.2 years, 44 (35%) patients had HF/death, 36 (29%) patients died. Patients with RV-LV AD ≥ 86 ms (lower quartile) had significantly lower risk of HF/death [hazard ratio (HR): 0.44; 95% confidence interval (95% CI): 0.23–0.82; P = 0.001] and all-cause mortality (HR: 0.48; 95% CI: 0.23–1.00; P = 0.05), compared with those with RV-LV AD < 86 ms. Patients with RV-LV AD ≥ 86 ms and LBBB showed the greatest improvement in EF (28–36%; P<0.001), NT-proBNP (2771–1216 ng/mL; P < 0.001), and they had better HF-free survival (HR: 0.23, 95% CI: 0.11–0.49, P < 0.001) and overall survival (HR: 0.35, 95% CI: 0.16–0.75; P = 0.007). There was no difference in outcome by RV-LV AD in non-LBBB patients. Left bundle branch block patients with longer RV-LV activation delay at CRT implantation had greater improvement in NT-proBNP, EF, and significantly better clinical outcome.

28 September 2022 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
AAAstrid Apor
Astrid Apor
ABAndrea Bartykowszki
Andrea Bartykowszki
BSBálint Szilveszter
Bálint Szilveszter
AVAndrea Varga
Andrea Varga
FSFerenc I Suhai
Ferenc I Suhai
ANAnikó Ilona Nagy
Anikó Ilona Nagy
Whether hypoattenuated leaflet thickening (HALT) following transcatheter aortic valve implantation (TAVI) carries a risk of subclinical brain injury (SBI) is unknown. We investigated whether HALT is associated with SBI detected on magnetic resonance imaging (MRI), and whether post-TAVI SBI impacts the patients’ cognition and outcome. We prospectively enrolled 153 patients (age: 78.1 ± 6.3 years; female 44%) who underwent TAVI. Brain MRI was performed shortly post-TAVI and 6 months later to assess the occurrence of acute silent cerebral ischaemic lesions (SCIL) and chronic white matter hyperintensities (WMH). HALT was screened by cardiac computed tomography (CT) angiography (CTA) 6 months post-TAVI. Neurocognitive evaluation was performed before, shortly after and 6 months following TAVI. At 6 months, 115 patients had diagnostic CTA and 10 had HALT. HALT status, baseline, and follow-up MRIs were available in 91 cases. At 6 months, new SCIL was evident in 16%, new WMH in 66%. New WMH was more frequent (100 vs. 62%; P = 0.047) with higher median volume (319 vs. 50 mm3; P = 0.039) among HALT-patients. In uni- and multivariate analysis, HALT was associated with new WMH volume (beta: 0.72; 95%CI: 0.2–1.39; P = 0.009). The patients’ cognitive trajectory from pre-TAVI to 6 months showed significant association with the 6-month SCIL volume (beta: −4.69; 95%CI: −9.13 to 0.27; P = 0.038), but was not related to the presence or volume of new WMH. During a 3.1-year follow-up, neither HALT [hazard ratio (HR): 0.86; 95%CI: 0.202–3.687; P = 0.84], nor the related WMH burden (HR: 1.09; 95%CI: 0.701–1.680; P = 0.71) was related with increased mortality. At 6 months post-TAVI, HALT was linked with greater WMH burden, but did not carry an increased risk of cognitive decline or mortality over a 3.1-year follow-up (NCT02826200).

14 August 2008 in EP Europace
Verified
Journal Article
Open access
PDF file
SSSzabolcs SzilÁGyi
Szabolcs SzilÁGyi
BMBéla Merkely
Béla Merkely
EZEndre Zima
Endre Zima
VKValentina Kutyifa
Valentina Kutyifa
GSGÁBor SzűCs
GÁBor SzűCs
LGLÁSzl&Oacute GellÉR
LÁSzl&Oacute GellÉR
Phrenic nerve stimulation (PNS), which is often intolerable for the patient, is a known complication of resynchronization therapy. We describe a new, minimal invasive method for treating PNS. Untreatable PNS was found in nine cardiac resynchronization therapy patients with distal coronary sinus (CS) lead position 6 ± 6 (0.5–17) months after the implantation. Ablation catheter and Amplatz Left 2 type guiding catheter were introduced into the right atrium via the right femoral vein. Coronary sinus was cannulated with the Amplatz catheter, and on a normal guide wire, a coronary stent was introduced beside the lead into the side branch in seven cases or a bigger stent into the CS in two patients. The ablation catheter was looped around the CS lead in the atrium with bent tip and was drawn backward together with the CS electrode. New lead positions were evaluated with electrophysiological measurements, and the suitable position was stabilized with inflation of the stent. Pericardial effusion was not detected on post-operative echocardiography. After repositioning, suitable pacing parameters were registered (threshold: 1.6 ± 1.1 V; 0.5 ms, impedance: 565 ± 62 ohm). Phrenic nerve stimulation was not found with 7.5 V; 1.5 ms pacing. During follow-up (7.7 ± 4.6 months), stable pacing threshold and impedance values were measured; transient and reprogrammable PNS was present in only one patient. Coronary sinus electrode reposition using the femoral approach seems to be a safe and effective procedure, which means smaller burden for the patients compared with the established reposition operation. The technique can be used successfully if the CS lead is in a distal position.